<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982198</url>
  </required_header>
  <id_info>
    <org_study_id>CEA2019-05K</org_study_id>
    <nct_id>NCT04982198</nct_id>
  </id_info>
  <brief_title>Robotic-assisted Versus Conventional Total Knee Arthroplasty</brief_title>
  <official_title>Robotic-assisted Versus Conventional Total Knee Arthroplasty: A Multicenter and Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective and randomized controlled pre-market clinical Trial. Study&#xD;
      subjects will be randomized into one of two operative groups: 1) TKA assisted with ROSA® Knee&#xD;
      System; 2) TKA with conventional surgical instrumentation.&#xD;
&#xD;
      The objective of this clinical trial is to measure the effectiveness and safety of the ROSA®&#xD;
      Knee System in assisting surgeons with bone resections and implant positioning optimization&#xD;
      through early clinical and radiographic outcomes compared with conventional surgical&#xD;
      instrumentation in total knee arthroplasty (TKA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mechanical axis alignment</measure>
    <time_frame>6 weeks (±2 week) postoperatively</time_frame>
    <description>Deviation from neutral mechanical axis alignment based on full-leg weight-bearing X-ray at 6 weeks (±2 week) postoperatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronal Lower Limb Alignment</measure>
    <time_frame>6 weeks (±2 week) postoperatively</time_frame>
    <description>Coronal Lower Limb Alignment based on full-leg weight-bearing X-ray at 6 weeks (±2 week) postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Total Knee Arthoplasty</condition>
  <arm_group>
    <arm_group_label>TKA assisted with ROSA® Knee System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TKA assisted with ROSA® Knee System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKA with conventional surgical instrumentation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TKA with conventional surgical instrumentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ROSA assisted TKA</intervention_name>
    <description>Robotic assisted total knee arthroplasty</description>
    <arm_group_label>TKA assisted with ROSA® Knee System</arm_group_label>
    <arm_group_label>TKA with conventional surgical instrumentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is age between 18 and 85 years old, inclusive;&#xD;
&#xD;
          2. Patient qualifies for a primary TKA based on the investigator's clinical judgement;&#xD;
&#xD;
          3. Patient is a candidate for commercially available Persona® Knee Joint Prosthese which&#xD;
             is compatible with the ROSA® Knee System;&#xD;
&#xD;
          4. Patient is willing and able to provide written Informed Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient planning to receive bilateral TKA surgery within 3 months;&#xD;
&#xD;
          2. Patient who has undergone revision surgery for partial or total knee arthroplasty of&#xD;
             the ipsilateral knee；&#xD;
&#xD;
          3. Bone tumor patient who has undergone bilateral TKA;&#xD;
&#xD;
          4. Stable, painless ipsilateral knee arthrodesis within a satisfactory function and&#xD;
             position;&#xD;
&#xD;
          5. Patient who has received partial or total knee arthroplasty for the contralateral knee&#xD;
             within 6 months prior to scheduled primary TKA;&#xD;
&#xD;
          6. Patient has active, local infection or previous intra-articular infection in the&#xD;
             affected joint;&#xD;
&#xD;
          7. Insufficient bone stock on femoral or tibial surfaces;&#xD;
&#xD;
          8. Skeletal immaturity;&#xD;
&#xD;
          9. Osteomalacia or any metabolic disorder which may impair bone formation;&#xD;
&#xD;
         10. Patient has neurologic disorders (e.g. Stroke);&#xD;
&#xD;
         11. Patient hs diseases that could lead to prosthesis instability, failure of prosthesis&#xD;
             fixation or postoperative complications (e.g. Arthrodesis, Scoliosis, Lumbar Stenosis)&#xD;
&#xD;
         12. Patient has a hip pathology with significant bone loss (e.g. avascular necrosis of the&#xD;
             femoral head with collapse, severe dysplasia of the femoral head or the acetabulum);&#xD;
&#xD;
         13. Patient has hip pathology severely limiting range of motion (e.g. arthrodesis, severe&#xD;
             contractures, chronic severe dislocation);&#xD;
&#xD;
         14. Patients with severe knee instability caused by incomplete collateral ligaments,&#xD;
             cruciate ligaments, and posterolateral structural injury;&#xD;
&#xD;
         15. Rheumatoid arthritis accompanied by an ulcer of the skin or history of recurrent&#xD;
             breakdown of the skin;&#xD;
&#xD;
         16. Patient has severe angular knee deformity of &gt;20° varus or &gt;20° valgus;&#xD;
&#xD;
         17. Patient has a known or suspected sensitivity or allergy to one or more of the implant&#xD;
             materials;&#xD;
&#xD;
         18. Patient has other contraindications specified by the implant manufacturer;&#xD;
&#xD;
         19. Patient is pregnant or considered a member of a protected population (e.g. prisoner,&#xD;
             mentally incompetent);&#xD;
&#xD;
         20. In the past 1 month participated in or is participating in clinical trials related to&#xD;
             other drugs and medical devices;&#xD;
&#xD;
         21. Any other conditions that the investigator considers inappropriate for participation&#xD;
             in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wang Lydia</last_name>
    <phone>021-2220</phone>
    <phone_ext>6116</phone_ext>
    <email>lydia.wang@zimmerbiomet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonggang Zhou</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

